Safety and Efficacy of Inhaled Tissue Plasminogen Activator (tPA) for the Acute Treatment of Pediatric Plastic Bronchitis

Trial Profile

Safety and Efficacy of Inhaled Tissue Plasminogen Activator (tPA) for the Acute Treatment of Pediatric Plastic Bronchitis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Alteplase (Primary)
  • Indications Bronchitis
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jun 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 24 May 2017 This study is supported by an FDA orphan drug R01, as reported in an abstract presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top